Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
The Angeles Clinic and Research Institute, Los Angeles, California UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California University of Colorado Cancer Center, Aurora, Colorado George Washington University, Washington D.C., District of Columbia Orlando Health UF Health Cancer Center, Orlando, Florida The University of Chicago Medicine, Chicago, Illinois Massachusetts General Hospital, Boston, Massachusetts Dana Farber Cancer Institute, Boston, Massachusetts Henry Ford Hospital, Detroit, Michigan Washington University, St Louis, Missouri John Theurer Cancer Center, Hackensack, New Jersey NYU Langone Health-Perlmutter Cancer Center, New York, New York Carolina BioOncology Institute, Huntersville, North Carolina Oregon Health Sciences University, Portland, Oregon Sara Cannon Research Institute Tennessee, Nashville, Tennessee Australia
Southside Cancer Center, Miranda, New South Wales Melanoma Institute Australia, Wollstonecraft, New South Wales Austin Hospital, Melbourne, Victoria One Clinical Research, Nedlands, Western Australia Spain
NEXT Oncology Barcelona, Barcelona NEXT Oncology Madrid, Madrid United Kingdom
Beatson West of Scotland Cancer Centre, Glasgow, Scotland Queen Elizabeth Hospital Birmingham, Birmingham University College London Hospitals NHS Foundation Trust, London Guy's and St. Thomas' NHS Foundation Trust, London Imperial College London, London Churchill Hospital, Oxford University Hospital Southampton NHS Foundation Trust, Southampton